Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corporation

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Boston Scientific is reviewing long term results from patients who ha...

Boston Scientific’s Long-Term ESG Study: What Termination Means for Obesity Investment Sentiment

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Boston Scientific (BSX), Ionis Pharmaceuticals (IONS) and Conmed ...

Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), Ionis Pharmaceuticals (IONS) and Conmed (CNMD)

Blackstone Minerals Ltd ( ($AU:BSX) ) has provided an update. Blackstone Minerals has advanced work on a pre-feasibility study for the Mankayan cop...

Blackstone advances Mankayan pre-feasibility study with strong cash backing

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rezolute (RZLT) and Boston Scientific (BSX) with bul...

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)

FST Corp ( ($KBSX) ) has shared an update. On July 28, 2026, FST Corp. released unaudited condensed consolidated financial statements for the three...

FST Corp. Posts Stronger Q2 2026 Results and Launches $3 Million Share Buyback

FST Corp ( ($KBSX) ) has shared an update. On July 25, 2026, FST Corp.’s board approved a restricted stock award program under its 2025 Equity Ince...

FST Corp. Launches New Restricted Stock Award Program Under 2025 Equity Plan

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific (BSX) and The Ensign Group (ENSG...

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and The Ensign Group (ENSG)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX), Intuitive Surgical (ISRG) a...

Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Intuitive Surgical (ISRG)

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Boston Scientific (BSX) is running a global study called “Evaluation ...

Boston Scientific’s FARAFLEX AFib Trial Steps Up the Pulsed Field Ablation Race

Goldman Sachs analyst David Roman maintained a Buy rating on Boston Scientific yesterday and set a price target of $57.00. The company’s shares clo...

Goldman Sachs Keeps Their Buy Rating on Boston Scientific (BSX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Ligand Pharma (LGND) wit...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BSX	$49.29	-0.03%	6.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BSX	$49.29	-0.0%	6.42M
3
4
5
6

BSX

BSX

Get Boston Scientific Corporation Data in Excel

Get Boston Scientific Corporation Data in Excel